Stock JSPR JASPER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Real-time Estimate Cboe BZX
Other stock markets
 12:16:10 2024-06-03 pm EDT 		5-day change 1st Jan Change
25.5 USD -1.75% Intraday chart for Jasper Therapeutics, Inc. +8.32% +229.21%
May. 31 Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 CI
May. 20 Transcript : Jasper Therapeutics, Inc. - Special Call

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target
MT
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65
MT
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset
MT
TD Cowen Initiates Jasper Therapeutics With Outperform Rating
MT
Capital One Initiates Jasper Therapeutics With Overweight Rating, $7 Price Target
MT
EF Hutton Assumes Jasper Therapeutics at Buy With $6.85 Price Target
MT
EF Hutton Raises Price Target on Jasper Therapeutics to $6.85 From $4, Maintains Buy Rating
MT
Credit Suisse Lowers Jasper Therapeutics' PT to $3 From $7 After Announcing Pipeline Reprioritization, Keeps Outperform Rating
MT
Oppenheimer Adjusts Jasper Therapeutics Price Target to $8 From $21, Maintains Outperform Rating
MT
EF Hutton Starts Jasper Therapeutics at Buy With $4 Price Target
MT
Credit Suisse Lowers Jasper Therapeutics' Price Target to $8 from $9 on Moderately Tempered Peak Market Share Assumption, Keeps Outperform Rating
MT
Cantor Fitzgerald Starts Jasper Therapeutics at Overweight With $10 Price Target
MT
Credit Suisse Trims Jasper Therapeutics' Price Target to $10 from $15, Keeps Outperform Rating
MT
Credit Suisse Starts Jasper Therapeutics at Outperform with $15 Price Target
MT
JASPER THERAPEUTICS : William Blair Initiates Jasper Therapeutics at Outperform Rating
MT
JASPER THERAPEUTICS : BMO Initiates Jasper Therapeutics at Outperform Rating With $19 Price Target
MT
Jasper Therapeutics : Shares Soar Midday After Initiated by Oppenheimer With Outperform Rating, $21 Price Target
MT
JASPER THERAPEUTICS : Oppenheimer Starts Jasper Therapeutics at Outperform with $21 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JSPR Stock
  4. News Jasper Therapeutics, Inc.
  5. Analyst Reco.